Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
[DOI] [PubMed] [Google Scholar] 131.Wakamatsu K, Ito S
1001-A G-CSF-MOBILIZED AUTOLOGOUS PERIPHERAL BLOOD CD34-POSITIVE CELL INFUSION THERAPY FOR HCV-RELATED DECOMPENSATED CIRRHOSIS Toru Nakamura 1,2 , Atsutaka Masuda 1,2 , Makoto Kako 3 , Hirayuiki Enomoto 4 , Masaki Kaibori 5 , Yasuyuki Fujita 6 , Kyoko Tanizawa 6 , Tetsuya Ioji 6 , Hideki Iwamoto 1,2 , Hironori Koga 1,2 , Hiroyuki Suzuki 1,2 , Tomoyuki Takashima 4 , Haruki Uojima 3,7 , Hidekazu Yamamoto 5 , Kazunori Yoh 4,8 , Atsuhiko Kawamoto 6 , Shuhei Nishiguchi 4,9 , Takuji Torimura 1,10 and Takumi Kawaguchi 1 , (1)Kurume University School of Medicine, (2)Research Center for Innovative Cancer Therapy, Kurume University, (3)Shonan Kamakura General Hospital, (4)Hyogo Medical University, (5)Kansai Medical University, (6)Foundation for Biomedical Research and Innovation at Kobe, (7)Research Institute, National Center for Global Health and Medicine, (8)Yoh Digestive Clinic, (9)Kano General Hospital, (10)Omuta City Hospital Background: Preclinical studies have shown that peripheral blood (PB)-CD34 + cell transplantation reduced established liver fibrosis and promote hepatic regeneration
Mechanisms inferred from animal models demand renewed scrutiny to establish genuine translational potential [639]
Understanding your individual biomarker and genetic profile may help you and your provider evaluate whether glutathione supplementation aligns with your realistic health goals
US$ 20.13
US$ 26.67
US$ 27.80
US$ 22.13
US$ 24.90
